Navigation Links
Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Apr 12, 2007 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that four posters containing preclinical data will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held from April 14 - 18, 2007 in Los Angeles, CA.

Details of the presentations are as follows:

-- Abstract #1494: EZN-2208, a novel polyethyleneglycol-SN38 conjugate, has potent antitumor activity in a panel of human tumor xenografts (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 8.)

-- Abstract #1496: EZN-2208, a novel poly ethylene glycol-SN38 conjugate, improves pharmacological properties of SN38 in mice and rats. (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 10.)

-- Abstract #4731: Customized positive PEG linkers for the delivery of antisense molecules (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 14.)

-- Abstract #4726: In vitro and in vivo evaluation of PEGylated anti-Bcl2 siRNA conjugates in a Bcl-2 over-expressing lung cancer model (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 9.)

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two o
'"/>




Page: 1 2

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Pulmonary Fibrosis Foundation (PFF) and Veracyte, ... the organizations are partnering on a U.S. patient ... with interstitial lung diseases (ILDs), including idiopathic pulmonary ... (INTENSITY) survey will assess the steps and time ...
(Date:8/27/2015)... 27, 2015  QB3@953—a San Francisco ... of California (UC) research institute and biotech accelerator— ... to identify and facilitate collaborations to translate early ... The agreement formalizes a relationship between ... team and creates a new channel for DPAc ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. 27, ... presenting at the Rodman & Renshaw 17th Annual Global Investment ... at the St. Regis Hotel, ORYZON will be represented by ... Dr. Buesa will present this ... at the Fontainebleau Room (2nd Floor).  The company is completing ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... EAST SETAUKET, N.Y., Dec. 19, 2011  An article in the ... of the National Academy of Sciences USA , reported ... therapeutic potential in a laboratory model of Gaucher disease  ... and president of Lixte said, "This is a novel ...
... MISSISSAUGA, Ontario, Dec. 19, 2011  Valeant Pharmaceuticals International, ... VRX) announced that effective December 16, 2011, the ... a dermatology unit of Sanofi (EURONEXT: SAN and ... International, Inc. Valeant Pharmaceuticals International, ...
Cached Medicine Technology:Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 2Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 3
(Date:8/27/2015)... ... August 27, 2015 , ... ... with Julia Glushko, professional Tennis player for Israel in the Women’s Tennis Association ... for all her training and recovery. , With a focus on technology and ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of ... third doctoral program at its main campus in Reading: Doctor of Nursing Practice. , ... to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... partnership agreement for quality market research promotion on the Internet. MarketPublishers.com is ... Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager at ...
(Date:8/27/2015)... TX (PRWEB) , ... August 27, 2015 , ... ... cutting edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and ... using a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells ...
Breaking Medicine News(10 mins):Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3
... Sept. 8 , , WHAT: ... growing radio shows-- The CEO Show-- draws a clever analogy ... upcoming Webinar taken from his book titled, Golf and the Art ... the research and educational arm of Beryl, the nation,s leading healthcare-exclusive call ...
... , , , ... Health Integrated, a leading provider of Health Management Solutions, has ... the health plan integrates the management of behavioral health benefits ... solution, Health Integrated will provide Blue Cross of Idaho with ...
... , Nurses to March for Employee ... in Single-Payer Systems , , SAN ... the largest union and professional association of nurses in U.S. history, ... the biennial convention of California,s largest RN organization, the California Nurses ...
... , , LOS ANGELES, Sept. 8 ... obesity epidemic and a general lack of healthy living. In his new ... Help of a Personal Trainer" ( published by AuthorHouse ), ... lost over 60 pounds with the help of a personal trainer, and ...
... , LONDON, Sept. 8 The 2009 Frost ... Risk Management Award is presented to Pronova BioPharma ASA. The ... FDA-approved omega-3 derived prescription drug. Branded Omacor in Europe ... a prescribed adjunct to diet for the treatment of elevated ...
... , WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ ... health care reform, a new analysis by the Center for ... receive benefits under the House health reform bill (H.R. 3200). ... for the new taxpayer-funded affordability credits, there is nothing in ...
Cached Medicine News:Health News:The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 2Health News:Health Integrated Enters into Agreement with Blue Cross of Idaho to 'Carve-in' Behavioral Health Management 2Health News:1,200 RNs Gather in San Francisco Tuesday: Take Next Step to Form Nation's Largest Ever Union of Nurses 2Health News:The Simple ABCs of Weight Loss and Fitness 2Health News:The Simple ABCs of Weight Loss and Fitness 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 2Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 4Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 5Health News:Health Bill Could Benefit 6.6 Million Illegals 2Health News:Health Bill Could Benefit 6.6 Million Illegals 3
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
4 mm blade. Flat handle....
9 mm button end blade. 15 mm long backcutting blade. Angled at 45 degrees. Flat handle. Designated most popular model or size....
10 mm blade, angled left. Flat handle....
Medicine Products: